Evidence map›Paper›PMID 33599905›Full record

ArticleTargeted oncology2021

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

Vanessa Wong, Margaret Lee, Rachel Wong, Jeanne Tie, Jeremy Shapiro, Jayesh Desai, Louise Nott, Simone Steel, Matthew Burge, Brigette Ma and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. BRAFWorld journal of gastrointestinal oncology · 2021
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Vanessa WongThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. wong.v@wehi.edu.au.ORCID 0000-0002-4323-8786
Margaret LeeThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Rachel WongThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Jeanne TieThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Jeremy ShapiroCabrini Health, Malvern, VIC, Australia.
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Louise NottRoyal Hobart Hospital, Hobart, TAS, Australia.
Simone SteelPeninsula Private Hospital, Frankston, VIC, Australia.
Matthew BurgeRoyal Brisbane and Women's Hospital, Herston, QLD, Australia.
Brigette MaDepartment of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Adnan KhattakFiona Stanley Hospital, Murdoch, WA, Australia.
Wei HongThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Peter GibbsThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Walter and Eliza Hall Institute of Medical Research · AUCabrini Hospital · AUChinese University of Hong Kong · HKFiona Stanley Hospital · AUFrankston Hospital · AUPeter MacCallum Cancer Centre · AURoyal Brisbane and Women's Hospital · AURoyal Hobart Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundB-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS) primaries. In metastatic CRC (mCRC), there is substantial overlap between the reported features of BRAFmt and of an RS primary.

objectivesTo explore the significance of BRAFmt in a left-side (LS) primary, we analysed data from a multi-site mCRC registry. Tumours distal to the splenic flexure were considered LS.

resultsOf 3380 patients enrolled from June 2009 to June 2020, 214 (13%) of 1657 with known status were BRAFmt: 127 (24%) of 524 RS and 87 (8%) of 1133 LS. LS versus RS BRAFmt were younger (mean 59.5 vs. 65.1 years; p = 0.01), whereas sex (48 vs. 59% female; p = 0.13), mismatch repair-deficiency (dMMR) (16 vs. 21%; p = 0.47), and overall survival (OS) (median 15.1 vs. 17.7 months; p = 0.98) were similar. LS BRAFmt versus LS BRAF wildtype (wt) were of similar age (59.5 vs. 61.3 years; p = 0.28) with more females (48 vs. 37%; p = 0.04), more dMMR (16 vs. 1%; p < 0.0001), and inferior OS (median 15.1 vs. 36.6 months; p < 0.0001). Initial treatment with chemotherapy plus an epidermal growth factor receptor inhibitor produced median progression-free survival (PFS) of 4.3 versus 12.3 months (p = 0.20) for LS BRAFmt (n = 9) versus LS BRAFwt (n = 104). Initial chemotherapy and bevacizumab produced a median PFS of 7.6 versus 11.6 months (p = 0.02) for LS BRAFmt (n = 36) versus LS BRAFwt (n = 438), respectively.

conclusionLS BRAFmt cancers share many features with RS BRAFmt cancers, including poor survival outcomes. Mature data on the activity of BRAF-targeted therapies in the first-line setting are eagerly awaited.

Indexed as

Colorectal NeoplasmsFemaleHumansMaleMutationNeoplasm MetastasisProto-Oncogene MasProto-Oncogene Proteins B-rafBRAF protein, humanMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins B-raf

Identifiers

PMID33599905
OpenAlexW3130286961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.